CDX-3379-a differentiated human monoclonal antibody designed to block the activity of ErbB3
CDX-3379 is a human monoclonal antibody that uniquely blocks the activity of ErbB3
is expressed in many cancers, including head and neck squamous cell cancer and is believed to be an important receptor regulating cancer cell growth and survival as well as resistance to targeted therapies.
EGFR (Epidermal growth factor receptor) belongs to the erbB family of closely related receptor tyrosine kinases, which include erbB1 (Also known as EGFR), erbB2 (HER2), erbB3
, and erbB4.
Lastly, their data suggests that miR203 may constitute a new prognostic factor in canine oral melanoma, and that miR-205 acts as a tumoral suppressor through targeting the ERBB3
gene in canine and human melanoma cells (NOGUCHI et al., 2013).
receptor in cancer and cancer gene therapy.
The family of receptors in this group is made up of four homologous receptors: epidermal growth factor receptor (ErbB1/EGFR/HER1), HER2 (HER2/neu), ErbB3
(HER3) and ErbB4 (HER4) (3-5).
Upon further analysis of these fetal muscle cells two new cell surface markers called ERBB3
and NGFR were discovered; this enabled the researchers to precisely isolate muscle cells from human tissue and separate them from various cell types created using human pluripotent stem cells.
Li et al., "An ErbB3
antibody, MM-121, is active in cancers with ligand-dependent activation," Cancer Research, vol.
Vorinostat, a HDAC inhibitor via inducing ubiquitination and lysosome degradation, downregulates the expression and signaling of all three receptors EGFR, ErbB2, and ErbB3
together with reversion of EMT in EGFR TKI gefitinib-resistant cells and therefore enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck .
Owens et al., "Conditional loss of ErbB3
delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling," Cancer Research, vol.
Mitsudomi et al., "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3
signaling," Science, vol.